142 related articles for article (PubMed ID: 7874568)
1. Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in advanced, measurable breast carcinoma.
Langer CJ; Catalano R; Weiner LM; Scher R; Bagchi P; Saren B; Comis RL
Cancer Invest; 1995; 13(2):150-9. PubMed ID: 7874568
[TBL] [Abstract][Full Text] [Related]
2. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the Hoosier Oncology Group.
Roth BJ; Sledge GW; Williams SD; Meyer SC; Ansari R; Fisher WB
Cancer; 1991 Jul; 68(2):248-52. PubMed ID: 2070321
[TBL] [Abstract][Full Text] [Related]
4. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
Bellmunt J; Ribas A; Eres N; Albanell J; Almanza C; Bermejo B; Solé LA; Baselga J
Cancer; 1997 Nov; 80(10):1966-72. PubMed ID: 9366300
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
Saxman SB; Propert KJ; Einhorn LH; Crawford ED; Tannock I; Raghavan D; Loehrer PJ; Trump D
J Clin Oncol; 1997 Jul; 15(7):2564-9. PubMed ID: 9215826
[TBL] [Abstract][Full Text] [Related]
6. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
Loehrer PJ; Einhorn LH; Elson PJ; Crawford ED; Kuebler P; Tannock I; Raghavan D; Stuart-Harris R; Sarosdy MF; Lowe BA
J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
[TBL] [Abstract][Full Text] [Related]
7. High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
Lamar RE; Greco FA; Johnson DH; Murphy PB; Hainsworth JD
Cancer; 1994 Apr; 73(7):1842-8. PubMed ID: 8137208
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
Dodd PM; McCaffrey JA; Mazumdar M; Scher H; Vlamis V; Higgins G; Herr H; Bajorin DF
Cancer; 1999 Mar; 85(5):1145-50. PubMed ID: 10091800
[TBL] [Abstract][Full Text] [Related]
11. A Phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma.
Morrell LE; Lee YJ; Hurley J; Arias M; Mies C; Richman SP; Fernandez H; Donofrio KA; Raub WA; Cassileth PA
Cancer; 1998 Feb; 82(3):503-11. PubMed ID: 9452268
[TBL] [Abstract][Full Text] [Related]
12. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
[TBL] [Abstract][Full Text] [Related]
13. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
Nakanishi S; Matsuzaki M; Morikawa H; Nakano M; Komatsu H
Hinyokika Kiyo; 2004 Oct; 50(10):667-71. PubMed ID: 15575216
[TBL] [Abstract][Full Text] [Related]
15. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium.
Long HJ; Nelimark RA; Podratz KC; Suman V; Keeney GL; Nikcevich DA; Kugler JW; Rowland KM; Kardinal CG; Wos EJ
Gynecol Oncol; 2006 Mar; 100(3):501-5. PubMed ID: 16185755
[TBL] [Abstract][Full Text] [Related]
16. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.
Sternberg CN; Yagoda A; Scher HI; Watson RC; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N; Weiselberg LR
J Urol; 1988 Mar; 139(3):461-9. PubMed ID: 3343727
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature.
Long HJ; Rayson S; Podratz KC; Abu-Ghazaleh S; Suman V; Hartmann LC; Levitt R; Nair S; Hatfield AK; Knost JA
Am J Clin Oncol; 2002 Dec; 25(6):547-51. PubMed ID: 12477995
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent endometrial carcinoma.
Long HJ; Langdon RM; Cha SS; Veeder MH; Pfeifle DM; Krook JE; Ebbert LP; Tschetter LK; Roshon SG
Gynecol Oncol; 1995 Aug; 58(2):240-3. PubMed ID: 7622111
[TBL] [Abstract][Full Text] [Related]
19. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
Gasparini G; Caffo O; Barni S; Frontini L; Testolin A; Guglielmi RB; Ambrosini G
J Clin Oncol; 1994 Oct; 12(10):2094-101. PubMed ID: 7931479
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.
Moore MJ; Iscoe N; Tannock IF
J Urol; 1993 Oct; 150(4):1131-4. PubMed ID: 8371371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
